Fasenra vs Nucala
A side-by-side look at two respiratory medications advertised on TV. Informational only — not medical advice.
| US Fasenra | US Nucala | |
|---|---|---|
| Generic name | benralizumab | mepolizumab |
| Drug class | IL-5 Receptor Antagonist (Biologic) | IL-5 Antagonist (Biologic) |
| Treats | Severe eosinophilic asthma | Severe eosinophilic asthma, COPD, nasal polyps |
| Category | Respiratory | Respiratory |
| Manufacturer | AstraZeneca | GSK |
| Year approved | 2017 | 2015 |
| FDA warning | No boxed warning | No boxed warning |
| Est. TV ad spend | $80M | $75M |
| Common side effects | Headache, Sore throat, Allergic reactions, Injection site reactions | Headache, Injection site reactions, Back pain, Fatigue |
Frequently asked questions
Is Fasenra or Nucala better?
Neither is universally "better." Fasenra (benralizumab) and Nucala (mepolizumab) are both used for respiratory, but the right choice depends on your medical history, insurance and your doctor's guidance. This comparison is informational only.
What's the difference between Fasenra and Nucala?
Fasenra is a IL-5 Receptor Antagonist (Biologic) made by AstraZeneca, while Nucala is a IL-5 Antagonist (Biologic) made by GSK. See the table above for a side-by-side breakdown.
Which one spends more on TV ads?
Fasenra has the larger estimated TV advertising budget of the two.